Skip to main content

Table 3 Prognostic factors for overall survival of patient with CRC

From: Clinicopathologic characteristics and prognosis of synchronous colorectal cancer: a retrospective study

Characteristics Univariate analysis Multivariate analysis
HR (95%CI) P valuea HR (95%CI) P valuea
Gender
 Female 1 (Reference)   
 Male 1.17 (0.90–1.51) 0.235   
EOCRC or LOCRC
 LOCRC 1 (Reference) 1 (Reference)
 EOCRC 0.40 (0.27–0.59) < 0.001 0.35 (0.24–0.53) < 0.001
Family history of tumours
 No 1 (Reference) 1 (Reference)
 Yes 0.34 (0.12–0.90) 0.030 0.56 (0.20–1.53) 0.257
BMI (kg/m2)
 18.5 to 24 1 (Reference) 1 (Reference)
 < 18.5 1.59 (1.12–2.27) 0.009 1.82 (1.26–2.62) 0.001
 ≥ 24 0.86 (0.65–1.15) 0.314 1.05 (0.78–1.41) 0.762
Haemoglobin (g/L)
 > 110 1 (Reference) 1 (Reference)
 ≤ 100 1.62 (1.26–2.07) < 0.001 1.38 (1.05–1.81) 0.022
Platelet counts (109/L)
 ≤ 300 1 (Reference)   
 > 300 1.12 (0.85–1.47) 0.414   
WBC (109/L)
 ≤ 10 1 (Reference)   
 > 10 0.94 (0.59–1.49) 0.783   
CEA (ng/mL)
 ≤ 10 1 (Reference) 1 (Reference)
 > 10 2.84 (2.22–3.64) < 0.001 1.47 (1.11–1.94) 0.006
CA199 (kU/L)
 ≤ 27 1 (Reference) 1 (Reference)
 > 27 2.58 (2.01–3.32) < 0.001 1.22 (0.91–1.62) 0.186
CA125 (kU/L)
 ≤ 35 1 (Reference) 1 (Reference)
 > 35 3.94 (2.89–5.36) < 0.001 1.95 (1.36–2.79) < 0.001
CA153 (kU/L)
 ≤ 25 1 (Reference) 1 (Reference)
 > 25 2.94 (1.51–5.73) 0.002 2.31 (1.13–4.73) 0.022
AFP (ng/mL)
 ≤ 7 1 (Reference)   
 > 7 0.81 (0.41–1.57) 0.527   
Type of ascites
 No 1 (Reference) 1 (Reference)
 Serous 1.53 (1.00–2.35) 0.051 0.72 (0.45–1.16) 0.179
 Bloody 5.40 (2.67–10.94) < 0.001 2.86 (1.29–6.34) 0.010
Tumor location
 Right colon 1 (Reference) 1 (Reference)
 Left colon 0.66 (0.46–0.93) 0.018 0.70 (0.48–1.02) 0.067
 Rectum 0.74 (0.54–1.01) 0.057 1.02 (0.72–1.44) 0.909
 Multiple segment 0.85 (0.54–1.35) 0.496 0.76 (0.44–1.32) 0.326
Radical or palliative surgery
 Radical 1 (Reference) 1 (Reference)
 Palliative 9.49 (7.37–12.23) < 0.001 3.99 (2.42–6.56) < 0.001
 (y)pTNM staging
 0–I 1 (Reference) 1 (Reference)
 II 0.92 (0.63–1.35) 0.672 0.70 (0.48–1.02) 0.067
 III 0.82 (0.56–1.21) 0.314 1.02 (0.72–1.44) 0.908
 IV 1.02 (0.66–1.56) 0.933 0.76 (0.44–1.32) 0.326
Number of retrieved lymph nodes
 < 12 1 (Reference) 1 (Reference)
 ≥ 12 1.57 (1.14–2.16) 0.006 1.43 (1.02–2.00) 0.041
Gross classification
 Mass type 1 (Reference) 1 (Reference)
 Infiltration type 3.05 (1.24–7.51) 0.015 1.14 (0.40–3.23) 0.802
 Ulceration type 1.06 (0.82–1.37) 0.655 0.82 (0.62–1.08) 0.160
Histological type
 Classical adenocarcinoma 1 (Reference)   
 Mucinous adenocarcinoma 1.03 (0.65–1.62) 0.915   
 Signet ring cell carcinoma 0 (0-Inf) 0.990   
Differentiation grade
 Well differentiated 1 (Reference) 1 (Reference)
 Moderately differentiated 1.26 (0.91–1.77) 0.167 1.06 (0.75–1.49) 0.759
 Poorly differentiated 1.93 (1.29–2.89) 0.001 1.30 (0.83–2.04) 0.252
Vessel invasion
 Negative 1 (Reference) 1 (Reference)
 Positive 2.62 (1.98–3.48) < 0.001 1.44 (1.03–2.01) 0.033
Neural invasion
 Negative 1 (Reference) 1 (Reference)
 Positive 2.07 (1.56–2.73) < 0.001 1.04 (0.75–1.43) 0.824
Ki67 expression
 Low 1 (Reference)   
 Moderate 0.81 (0.48–1.37) 0.429   
 High 0.84 (0.54–1.32) 0.459   
MMR status
 pMMR 1 (Reference) 1 (Reference)
 dMMR 0.45 (0.25–0.80) 0.007 0.67 (0.36–1.27) 0.221
Tumor type
 PCRC 1 (Reference) 1 (Reference)
 SCRC 1.36 (1.05–1.76) 0.021 1.02 (0.75–1.40) 0.889
  1. HR hazard ratio, CI confidence interval. aThe bolded P value was statistically significant (P < 0.05)